AlphaFold predicted structure
MGAT2 · Q10469

Mean pLDDT
84.9/ 100
Confident
447 residues
Confidence breakdown
- Very high(≥ 90)72%
- Confident(70–90)6%
- Low(50–70)4%
- Very low(< 50)18%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase
Annotations refreshed 10 hours ago.
Diagnostic Grade (Green)
Congenital disorders of glycosylation
BIALLELIC, autosomal or pseudoautosomalDDG2P
BIALLELIC, autosomal or pseudoautosomalIntellectual disability
BIALLELIC, autosomal or pseudoautosomalLikely inborn error of metabolism
BIALLELIC, autosomal or pseudoautosomalUndiagnosed metabolic disorders
BIALLELIC, autosomal or pseudoautosomalFetal anomalies
BIALLELIC, autosomal or pseudoautosomalChildhood onset dystonia, chorea or related movement disorder
Fetal hydrops
BIALLELIC, autosomal or pseudoautosomalMGAT2-congenital disorder of glycosylation
congenital disorder of glycosylation
congenital disorder of glycosylation type II
COVID-19
Abnormal glycosylation
Abnormal facial shape
Global developmental delay
hereditary disease
autoimmune disorder of musculoskeletal system
corneal neovascularization
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase
Plays an essential role in protein N-glycosylation. Catalyzes the transfer of N-acetylglucosamine (GlcNAc) onto the free terminal mannose moiety in the core structure of the nascent N-linked glycan chain, giving rise to the second branch in complex glycans
MGAT2 · Q10469

Mean pLDDT
84.9/ 100
Confident
447 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0